FDA Grants Approval for New TMB-H Cancer Treatment
Regulators approved pembrolizumab-based therapies for patients with solid tumors and updated the mutational burden threshold.
Updated on Oct. 22, 2026 in Cancer
Live Poll
Should the FDA require higher efficacy thresholds for cancer drugs before granting final approval?
The FDA has granted traditional approval for pembrolizumab and its combination with berahyaluronidase alfa-pmph to treat unresectable or metastatic solid tumors. This approval applies to patients with high tumor mutational burden status, defined as 13 or more mutations per megabase.
Why it matters
The FDA updated the threshold to 13 mutations per megabase because clinical efficacy was not confirmed for patients with mutation levels between 10 and 13. This change refines the criteria for patients who have progressed following prior treatment and have no satisfactory alternatives.
In the KEYNOTE-158 trial, 220 patients showed an objective response rate of 36 percent. Additionally, 58 percent of these patients achieved a duration of response lasting 12 months or longer.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and ensuring the safety of medical treatments in the United States.
The details
The treatment regimen, which includes a 200 mg dosage frequency for up to 24 months, requires patients to have specific solid tumor status. The safety profile for these therapies remains consistent with previous monotherapy evaluations conducted by the agency.
Timeline
October 16, 2026: The FDA granted traditional approval for the drug combination.
Health Landscape
The FDA's decision to grant traditional approval relies on the data collected through the KEYNOTE-158 clinical trial program. This underscores the evolution of precision oncology as researchers continue to refine genetic thresholds for targeted therapies.
Patients with solid tumors should consult with their oncologists to determine if their mutational profile meets the new 13 mutations per megabase requirement. This updated standard helps ensure that treatment options are provided to those most likely to respond based on verified clinical data.
The takeaway
The adjustment of the tumor mutational burden threshold highlights the importance of precise genetic testing in oncology. Patients and providers should focus on these evolving metrics to ensure access to the most effective, FDA-approved therapeutic interventions.
Further reading
For more information on current treatment standards, visit the Cancer section.
Live Poll
Should the FDA require higher efficacy thresholds for cancer drugs before granting final approval?
